You’re not on your own.
A private peer-support group for people with two copies of the APOE ε4 gene who have also been told they’re amyloid positive (by a brain scan, spinal fluid or blood test), and for the people who care for them.
Being APOE ε4/ε4 is a risk factor, not a diagnosis. Not everyone with two copies develops dementia, and when symptoms start varies a lot from person to person. But if you’ve also learned you’re amyloid positive, perhaps with a family history, it’s natural to feel worried. You may then find that the new Alzheimer’s treatments approved in Australia aren’t approved for people with two copies of ε4, because the risk of a side effect called ARIA (brain swelling or small bleeds) is higher. This group is a place to meet others in the same position, who understand.
Who it’s for
Some changes. You’re ε4/ε4 and amyloid positive, with early memory or thinking changes.
No symptoms yet. You’re ε4/ε4 and amyloid positive, with no memory or thinking changes.
Carers & family. You support someone in either group.
Still waiting on an amyloid result? You can register now, or call Rod to talk it through.
My father lived with Alzheimer’s. I’ve worked in this field for over 26 years. And I’m ε4/ε4 myself. For me this is a crusade, not a career.Rod Fanner, founder
What you’ll find
Small get-togethers in person and online, a private members’ forum moderated by Rod, and plain-English help making sense of research.
See what’s includedHealth professional?
Somewhere to send your ε4/ε4 patients. Referral takes two minutes, with your patient’s consent.
Refer a patientUnderstanding ε4/ε4
Plain-English information for people with two copies of APOE ε4, and the people who support them.
In short
- About 2 to 3 in every 100 people are ε4/ε4. [1] They make up around 15% or more of people with Alzheimer’s. [2]
- Almost everyone with ε4/ε4 has Alzheimer’s brain changes (amyloid) by their mid-60s. [5] Having amyloid is not the same as having dementia. [9]
- In Australia, the EU, the UK and Canada, the amyloid-targeting treatments exclude ε4/ε4. The US, Japan and China allow them, with warnings. [10] [11] [16] [17]
- Some new drug trials include people with ε4/ε4, including trontinemab trials with Australian sites. [31] [32]
- Lifestyle may help people with one copy. For two copies, the evidence is uncertain. [43]
- Since 8 October 2026, life insurers can’t use genetic test results. [47]
1. APOE: the basics
Everyone inherits two copies of the APOE gene, one from each parent. [45] It comes in three common versions: ε2, ε3 and ε4.
2. What ε4/ε4 means: the latest science
The largest study of ε4/ε4, published in Nature Medicine in 2024, found that by age 65 nearly all had abnormal amyloid in spinal fluid and 75% had a positive amyloid scan. Symptoms started at an average age of 65.1. The researchers proposed that ε4/ε4 be seen as a distinct genetic form of Alzheimer’s. [5]
But dementia is not certain, and timing varies. In a large study of healthy older Australians and Americans, 26.6% of people with ε4/ε4 developed dementia by age 85. [6] Other genes shift the risk too: among ε4/ε4 people, those with the highest and lowest background genetic risk differed by 37 percentage points in dementia by 85, equal to 7 to 10 years in age of onset. [7]
3. Amyloid, tau and testing
Alzheimer’s moves through stages: brain changes without symptoms (preclinical), mild cognitive impairment (MCI), then dementia. Amyloid can be measured by PET scan, spinal fluid test or, since July 2026 in Australia, a TGA-approved pTau217 blood test. [8] The blood test is for people with memory concerns, not screening people without symptoms. [8] [9]
4. Why the new treatments exclude ε4/ε4 in Australia
The TGA approved donanemab (Kisunla) in May 2025 and lecanemab (Leqembi) in September 2025, both only for people with no ε4 or one copy. [10] [11] The TGA found safety and effectiveness had not been established for two copies. [10] The main concern is ARIA, swelling or small bleeds in the brain, usually without symptoms but occasionally serious:
5. Amyloid treatments and ε4/ε4 around the world
| Country or region | Lecanemab (Leqembi) | Donanemab (Kisunla) |
|---|---|---|
| United States | Includes ε4/ε4, boxed warning [16] | Includes ε4/ε4, boxed warning [17] |
| Japan | Includes ε4/ε4, boxed warning [16] | Includes ε4/ε4 [17] |
| China | Includes ε4/ε4 [18] [19] | Includes ε4/ε4 [17] |
| South Korea | Includes ε4/ε4 in practice [20] [21] | Not confirmed |
| European Union | Excludes ε4/ε4 [22] | Excludes ε4/ε4 [17] |
| United Kingdom | Excludes ε4/ε4 [23] | Excludes ε4/ε4 [24] |
| Canada | Excludes ε4/ε4 [25] | Excludes ε4/ε4 [26] |
| Australia | Excludes ε4/ε4 [10] | Excludes ε4/ε4 [11] |
Lecanemab is approved in 53 countries and regions [27]; Lilly says donanemab is approved regardless of APOE4 status in many countries beyond the US, Japan and China. [17] Not every country’s label is published.
What could change. A gentler donanemab starting dose cut ARIA-E in ε4/ε4 from 57% to 19%. [28] For lecanemab, a slower start reduced ARIA in ε4 carriers, and a subcutaneous starting dose is now approved in the US, China and Japan. [27] The oral drug valiltramiprosate was trialled only in ε4/ε4 and missed its main goal, with signals in early-stage patients. [29] A gene therapy, LX1001, was safe in a small early trial. [30]
6. Drug trials that include ε4/ε4
| Drug | Trial | Who | ε4/ε4 | Australia |
|---|---|---|---|---|
| Trontinemab (Roche) | TRONTIER 1 and 2, phase 3 | MCI or mild dementia | Allowed [31] | 9 sites in NSW, SA, Vic and WA [32] |
| Trontinemab (Roche) | PrevenTRON, phase 3, recruiting | No symptoms, aged 55–80, high pTau217 [34] | Not yet stated publicly | Royal Prince Alfred and KaRa Institute, Sydney [33] |
| Lecanemab, donanemab | AHEAD 3-45, TRAILBLAZER-ALZ 3 | No symptoms | Included; closed to new people [35] [36] | Not confirmed |
Trial status changes often. Ask your specialist or register with StepUp for Dementia Research. [37]
7. What options exist now
- Clinical trials (section 6).
- Existing medicines. Donepezil, rivastigmine, galantamine and memantine are on the PBS for Alzheimer’s dementia, whatever your APOE type. [38]
- Plan ahead while well. Enduring power of attorney, advance care directive, will and finances.
8. Lifestyle and ε4
The 2024 Lancet Commission found that tackling 14 risk factors, including blood pressure, cholesterol, hearing loss, inactivity and isolation, could prevent or delay nearly half of dementia cases. [39] For ε4 the picture is mixed:
| Study | What it found |
|---|---|
| FINGER trial (Finland) | A lifestyle programme benefited thinking in ε4 carriers. [40] |
| US POINTER trial (2025) | Structured programme benefit was the same in carriers and non-carriers. [41] |
| Rotterdam Study | A healthy profile didn’t offset high genetic risk. [42] |
| JPSC-AD (Japan, 2026) | No significant difference in dementia risk for ε4/ε4, the only study to look at two copies separately. [43] |
Walking and sustained physical activity stood out for ε4 carriers. [44]
Our view. Look after your heart, hearing, sleep and fitness because they matter for your health. Don’t rely on lifestyle alone, and don’t blame yourself if changes come anyway.
9. Family and genetics
You received one ε4 from each parent. [45] Every biological child of someone with ε4/ε4 carries at least one ε4. [46] Brothers and sisters have at least a 1 in 4 chance of also being ε4/ε4. Testing is a personal choice; see a genetic counsellor first.
10. Insurance and privacy
From 8 October 2026, life insurers can’t use genetic test results for life, TPD, trauma or income protection cover. [47] The law covers genetic tests only. [48] Amyloid scans, blood biomarkers and diagnoses can still be asked about. Travel insurance is not covered. [49] Private health insurance is community rated and can’t be refused on health grounds. [50] Get independent advice before applying.
11. Looking after yourself
Learning an APOE result caused no significant rise in anxiety or depression overall, but people already distressed beforehand struggled more. [51] People without symptoms told their amyloid is raised often have negative feelings that ease but don’t fully go away. [52] Talking with others in the same position helps.
If you need help now: Lifeline 13 11 14 and Beyond Blue 1300 22 4636 [53], National Dementia Helpline 1800 100 500 [54], all 24/7. In an emergency call 000.
12. Questions to ask your doctor
- What do my results show: genotype, amyloid, or both?
- Do I have any signs of MCI now? Should I have a baseline assessment?
- Which risk factors should we work on first?
- Are there trials I could be eligible for?
- Should my family see a genetic counsellor?
General information, not medical, legal or financial advice. Last updated: November 2026. Reviewed by: [clinical reviewer to be confirmed]. Sources
What you’ll find
A private peer-support network for people who are APOE ε4/ε4 and amyloid positive, with or without symptoms, and the people who care for them. Independent, self-funded and open across Australia.
Why a network for ε4/ε4
- A distinct group. About 2 to 3 in 100 people, but 15% or more of people with Alzheimer’s. [1] [2] Brain changes and symptoms come earlier. [5]
- Left out of treatment in Australia. [10] [11]
- Learning the result is hard. Support matters most for people already distressed. [51] [52]
- No group built for it. Dementia Australia’s Connecting Peers supports people living with dementia and their carers. [58] We know of no Australian group for ε4/ε4, or for amyloid-positive people without symptoms.
- Peer support helps. Support groups may improve mood, quality of life and self-esteem in early dementia [55], benefit carers [56], and work online across distance. [57]
What members get
| What | What it means for you |
|---|---|
| People who get it | Small, friendly get-togethers in person, and online wherever you live in Australia |
| A private online forum | Members only and moderated by Rod, so you can talk openly. Your details stay private |
| The right conversation for you | One welcoming group, with its own space for people without symptoms, plus space for carers |
| Making sense of research | What new studies found and what they mean for you, ways to take part in research, and questions worth asking your doctor, in plain English |
| A stronger voice | Together, we can ask that people with ε4/ε4 are not left out of decisions about treatment |
What it is not
Not medical advice, not promotional, not trial recruitment and not a crisis service. Our founder worked in the pharmaceutical industry until 2026 and is open about it.
Ground rules: what’s said in the group stays in the group; share experiences, not medical advice; no promotion; be kind.
Privacy: health and genetic information is sensitive information under Australian privacy law. [59] We collect only what we need, never share or sell it, and delete it on request.
How to join
- Register online, or scan the QR code on the brochure with your phone camera.
- Answer the short questions and submit, even if you’re still waiting on an amyloid result.
- Rod will call you within a week for a relaxed welcome chat. No pressure.
Takes about two minutes. Use an email address that’s private to you.
Rod Fanner, founder. Over 26 years in Alzheimer’s care and support, and ε4/ε4 himself.
Somewhere to send your ε4/ε4 patients
A closed, independent peer-support forum for people who are APOE ε4 homozygous and amyloid positive, cognitively impaired or unimpaired, and the people who care for them. Open to patients in every Australian state and territory.
The gap
TGA-registered amyloid-targeting treatments indicated for APOE ε4 homozygotes1,2
of people with Alzheimer’s are ε4/ε4, compared with 2–3% of the population3
registered therapies for preclinical, amyloid-positive AD, at any APOE status
Your APOE ε4/ε4 patients are often younger, well-informed and acutely aware of their risk. Once they learn current treatments aren’t indicated for them, clinical trials become close to their only option, and there is almost no peer support built around their situation. This network fills that gap, alongside the care you already provide.
What the network offers your patients
A closed peer forum
Members-only and moderated by Rod. Online, open to patients in every state, plus face-to-face meet-ups. Member details stay private.
One forum, two conversations
Members with MCI or mild AD and those who are cognitively unimpaired share one forum, with a dedicated space for preclinical members.
Carers included
Partners and family get their own space, and are welcome alongside members.
Making sense of research
Plain-language help understanding what new research shows and what it means for ε4/ε4 patients, finding research opportunities, and preparing questions for you.
What it is not
Not medical advice. Clinical decisions stay with you and your patient.
Not promotional. Independent, self-funded and treatment-agnostic; no product is promoted.
Not trial recruitment. We don’t steer members to any specific study.
How to refer
- Patient is APOE ε4/ε4 and amyloid positive (PET, CSF or plasma p-tau217), with or without symptoms.
- With your patient’s consent, open the referral form, and give them the patient & carer flyer.
- Answer the short referral questions.
- Submit. Rod calls your patient within a week for a welcome chat, then forum access.
With your patient’s consent; contact details only.
About the founder
Rod Fanner has worked in Alzheimer’s disease for more than 26 years, from Aricept and Pfizer, through 12 years with Souvenaid at Nutricia, to Eli Lilly, where he worked until 2026. He volunteered with Dementia Australia for 15 years, has run patient and carer coffee groups since 2012, and is himself APOE ε4/ε4, amyloid positive and preclinical.
1. Kisunla (donanemab) Product Information, TGA, May 2025. 2. Leqembi (lecanemab) Product Information, TGA, Sept 2025. 3. Fortea J et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer’s disease. Nat Med 2024;30:1284–1291.
About the network
Independent, self-funded peer support and information. Not medical advice.
Why build an e4e4 support network?
Rod came to Alzheimer’s disease after his father was diagnosed with early-onset Alzheimer’s. More than 26 years later, he is himself APOE ε4/ε4, amyloid positive and preclinical.
The amyloid-targeting treatments approved in Australia aren’t approved for people with two copies of ε4, and aren’t approved for anyone who is amyloid positive without symptoms. People who are ε4/ε4 fall outside the approved treatment indications, clinical trials are often close to their only option, and there has been almost no support built around their situation.
Since leaving Eli Lilly, Rod has set up this network for people who are ε4/ε4 and amyloid positive, with or without symptoms, and for the people who care for them: somewhere to meet others in the same position, who understand.
For Rod, it has always been more than a job: he calls it “a crusade, not a career”.
About the founder
Rod Fanner · Alzheimer’s disease specialist · Patient and carer advocate
Rod Fanner has specialised in Alzheimer’s disease for more than 26 years. His pharmaceutical roles let him touch the lives of patients through the medicines he managed, both through the doctors he worked with and directly through the support groups he set up. He has built and led national teams through each major shift in treatment, from the first symptomatic therapies to today’s amyloid-targeting treatments.
At Pfizer, Rod specialised in Aricept and Alzheimer’s disease and headed the company’s Alzheimer’s disease team. He then spent 12 years at Nutricia, where he headed Souvenaid, recruited its national team and led its patient and carer support program, Souvenaid Connections.
Most recently, at Eli Lilly Australia, Rod recruited and led the national dementia neurology team. He led that team through the introduction of donanemab (Kisunla), one of the first disease-modifying treatments for early Alzheimer’s disease.
Alongside his corporate roles, Rod is a former Dementia Australia volunteer who spent 15 years educating medical students about dementia. Since 2012 he has also run independent coffee groups for people living with dementia and their carers, in Melbourne and across NSW, SA and WA.
Rod knows Australian dementia care from the commercial, clinical, family and personal sides. He is well connected with geriatricians, neurologists and advocacy organisations, and with many patients and carers who still call him to talk through their challenges. He understands what the new generation of treatments asks of patients, carers and the services that care for them.
Independence
The network is independent and self-funded. It is treatment-agnostic, promotes no product, and doesn’t recruit for clinical trials.
Privacy
Your details are kept private and used only for your membership. We never ask you to send test results, and you can ask us to remove your details at any time.
Sources
References for this website. Back to Understanding ε4/ε4
- Sant Pau Research Institute, May 2024. www.recercasantpau.cat
- Eisai / Biogen lecanemab data release, 2025. investors.biogen.com
- Farrer LA et al. JAMA 1997 (APOE meta-analysis). ncradbio.sitehost.iu.edu
- Alzheimer Europe, May 2024. www.alzheimer-europe.org
- Fortea J et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer’s disease. Nature Medicine 2024;30:1284–1291. www.nature.com
- ASPREE: APOE and dementia in a healthy older population. www.ncbi.nlm.nih.gov
- van der Lee SJ et al. Rotterdam Study, polygenic risk and APOE. repub.eur.nl
- RACGP newsGP. TGA authorises pTau217 blood test for Alzheimer’s disease, July 2026. www1.racgp.org.au
- HealthEd. Alzheimer’s blood test coming to Australia. www.healthed.com.au
- TGA. Registration of lecanemab, September 2025. www.tga.gov.au
- BioSpectrum Asia. Kisunla authorised in Australia, May 2025. www.biospectrumasia.com
- Alzheimer’s Association. Lecanemab APOE toolkit. www.alz.org
- ARIA by APOE genotype (table), PubMed Central. pmc.ncbi.nlm.nih.gov
- Dementia Australia. Donanemab and lecanemab. www.dementia.org.au
- healthdirect. Kisunla. www.healthdirect.gov.au
- Regulatory challenges of lecanemab. Neurological Sciences 2026. link.springer.com
- Eli Lilly. Kisunla authorised by the European Commission, September 2025. investor.lilly.com
- CCFDIE. Lecanemab approved by China NMPA, January 2024. www.ccfdie.org
- Real-world lecanemab in South China, 2025. www.ncbi.nlm.nih.gov
- Korean Dementia Association. Lecanemab appropriate use. pmc.ncbi.nlm.nih.gov
- Real-world lecanemab in South Korea, 2026. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency. Leqembi EPAR. www.ema.europa.eu
- Eisai / Biogen. Leqembi authorised in Great Britain, 2024. investors.biogen.com
- Eli Lilly. Kisunla authorised in Great Britain, October 2024. investor.lilly.com
- Eisai. Health Canada authorises Leqembi, 2025. www.eisai.com
- Eli Lilly Canada. Health Canada authorizes Kisunla (donanemab), May 2026. www.newswire.ca
- Alzforum. Leqembi profile, 2026. www.alzforum.org
- Eli Lilly. TRAILBLAZER-ALZ 6 modified titration, 2024. investor.lilly.com
- Alzheimer Europe. ALZ-801 phase 3 results in APOE4/4, 2025. www.alzheimer-europe.org
- LX1001 phase 1/2 results. Alzheimer’s & Dementia 2025. www.ncbi.nlm.nih.gov
- Alzforum. Roche phase 3 plans for trontinemab, 2025. www.alzforum.org
- ClinicalTrials.gov. TRONTIER 2 (NCT07170150). clinicaltrials.gov
- ClinicalTrials.gov. PrevenTRON (NCT07717411). clinicaltrials.gov
- Alzforum. Trontinemab profile, 2026. www.alzforum.org
- Alzforum. Secondary prevention studies of lecanemab and donanemab. www.alzforum.org
- ClinicalTrials.gov. TRAILBLAZER-ALZ 3 (NCT05026866). clinicaltrials.gov
- Dementia Australia. StepUp for Dementia Research. www.dementia.org.au
- PBS. Review of anti-dementia drugs. pbs.gov.au
- UCL. Lancet Commission on dementia, July 2024. www.ucl.ac.uk
- Solomon A et al. APOE genotype and cognitive change during a multidomain lifestyle intervention (FINGER). JAMA Neurology 2018;75:462–470. doi.org
- US POINTER (JAMA 2025). practicalneurology.com
- Licher S et al. Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk (Rotterdam Study). Nature Medicine 2019. doi.org
- Kyushu University. JPSC-AD lifestyle and APOE ε4, 2026. www.kyushu-u.ac.jp
- Alzheimer’s Association. AAIC 2025 public health takeaways. www.alz.org
- APOE inheritance and genotype frequencies, 2014. www.redalyc.org
- National Institute on Aging. Alzheimer’s disease genetics fact sheet. www.nia.nih.gov
- Insurance Business. Genetic testing ban now in force, October 2026. www.insurancebusinessmag.com
- Actuaries Institute. Genetic testing and life insurance. www.actuaries.asn.au
- Law Society Journal. Genetic results protected from life insurers. lsj.com.au
- privatehealth.gov.au. How private health insurance works. privatehealth.gov.au
- REVEAL Study Group. NEJM 2009. www.rti.org
- APOE and amyloid disclosure studies (table), 2021. pmc.ncbi.nlm.nih.gov
- healthdirect. Mental health helplines. www.healthdirect.gov.au
- Dementia Australia. National Dementia Helpline. www.dementia.org.au
- Leung P et al. Social support groups in dementia and MCI, 2015. www.mcmasteroptimalaging.org
- Queen’s University Belfast. Peer support for dementia carers. pure.qub.ac.uk
- Online peer support for people with dementia, 2025. www.ncbi.nlm.nih.gov
- Dementia Australia. Connecting Peers. www.dementia.org.au
- OAIC. Guide to health privacy. www.oaic.gov.au
Privacy policy
How we look after your personal, health and genetic information.
Effective 7 November 2026
The short version
- We collect only what we need to run the network and support you.
- We never sell your information, and we never share it with pharmaceutical companies, insurers, employers, researchers or trial sponsors.
- We never ask you to send us test results or medical records.
- You can see, correct or delete your information at any time.
Who we are
The APOE ε4/ε4 Patient & Carer Support Network (“the network”, “we”, “us”) is an independent, self-funded peer-support group run by Rod Fanner. It is not part of, or funded by, any company or organisation.
Our commitment
Information about your health and your genes is “sensitive information” under Australian privacy law, and it deserves the highest level of care. We follow the Australian Privacy Principles in the Privacy Act 1988 (Cth) in how we collect, use, store and share personal information, and we collect sensitive information only with your consent.
What we collect
When you register as a member or carer: your name, email, mobile number, state or territory and postcode, whether you are joining as a person with ε4/ε4 or as a carer, what you choose to tell us about your APOE and amyloid results and whether you have symptoms, whether you have seen a specialist and their name, how you’d like to take part, how you heard about us, and anything else you choose to tell Rod before the welcome call.
When a health professional refers you: your name and contact details, the referring professional’s name and practice, and their confirmation that you agreed to the referral. We ask for contact details only, not clinical records.
When you take part: notes Rod makes from your welcome chat to help him support you, your forum username and anything you post in the forum, and your attendance at get-togethers.
When you contact us: what you tell us by phone, email or message.
You don’t have to give us information you don’t want to share. If you’d rather stay anonymous or use a different name in the forum, tell us and we’ll help where we can.
How we use it
We use your information only to:
- confirm the network is right for you and welcome you;
- give you access to the forum and get-togethers, and keep you in the right space (members with symptoms, members without symptoms, or carers);
- contact you about the network, its events and research news in plain English;
- run, moderate and improve the network.
We will not use your information for advertising or marketing of any product, and we don’t recruit for clinical trials.
Who we share it with
We don’t share your information with anyone outside the network, except:
- Service providers we rely on to run the network: Google (registration forms and email), our forum platform [forum provider to be confirmed] and our website host. They store information for us and are not permitted to use it for their own purposes.
- If the law requires it.
- If we believe someone’s life, health or safety is at serious risk, we may contact emergency services.
If Rod tells your doctor anything about your involvement, it will only be because you asked him to.
Information stored overseas
Some of our service providers, including Google, may store information on servers outside Australia. We choose providers with strong security and privacy protections, but by registering you acknowledge your information may be stored overseas.
What you share inside the group
The forum is members only and moderated by Rod. Our ground rule is that what’s said in the group stays in the group. We can’t control what other members do, though, so please think before sharing anything you wouldn’t want repeated, and avoid posting other people’s personal details. Rod may remove posts that break the ground rules.
Keeping it safe
We keep information in password-protected accounts with two-step sign-in, limit access to Rod and anyone helping to run the network under the same rules, and don’t keep paper records of members’ health information.
How long we keep it
We keep your information while you are a member. If you leave, or ask us to delete your information, we will delete it within 30 days, unless the law requires us to keep it. If someone is referred but doesn’t join, we delete the referral details within three months.
This website
This website doesn’t use advertising or tracking cookies, and doesn’t run analytics. It loads its typeface from Google Fonts, which means Google receives your device’s internet address when you visit. Our website host may keep standard technical logs. The registration and referral forms are Google Forms, covered by Google’s privacy policy as well as this one.
Seeing, correcting or deleting your information
You can ask to see the information we hold about you, ask us to correct it, or ask us to delete it, at any time and free of charge. Contact us using the details below and we will respond within 30 days.
If something goes wrong
If your information is lost, or accessed by someone who shouldn’t have it, and this could cause you harm, we will tell you promptly, explain what happened and what we’re doing about it, and notify the Office of the Australian Information Commissioner where required.
Questions and complaints
Please contact Rod first and we will try to resolve your concern within 30 days. If you’re not satisfied, you can contact the Office of the Australian Information Commissioner (OAIC) on 1300 363 992 or at oaic.gov.au.
Members must be adults
The network is for people aged 18 and over. We don’t knowingly collect information about children.
Changes to this policy
If we change this policy, we will post the new version here with a new effective date, and tell members about significant changes.
Contact us
Rod Fanner, APOE ε4/ε4 Patient & Carer Support Network
0400 536 502 ·
Need to talk to someone now?
National Dementia Helpline: 1800 100 500
Free, 24 hours, 7 days
- Lifeline
Crisis support if things feel overwhelming.13 11 14 - Emergency
If you or someone else is in danger.000 - Your own doctor
For questions about your health, results and care. - Rod, at the network
Peer support, not a crisis service.0400 536 502